DAY 2: Monday, September 22, 2025
Program subject to change.
07:00 - 17:00
Registration Open
07:15 - 08:15
Career Mentoring and Networking Session, Sponsored by Lilly
08:30 - 09:30
Plenary Lecture 1
Predicting Altered Drug Disposition in Disease using Novel In Vitro and Modeling Tools
Kim Brouwer, UNC Chapel Hil, USA
09:30 - 10:00
Break, Posters, Exhibitors
Thought Leader Presentation
WuXi Apptec: 09:40 - 09:50
10:00 - 12:00
Concurrent Symposia 1 & 2
Symposium 1: Transporter-Enzyme Interplay & Drug-Drug Interactions in Health & Disease
Co-chairs: Xiaoyan Chu, Merck, USA; Jacqueline Tiley, University of North Carolina at Chapel Hill, USA
Transporter-Enzyme Interplay and Drug-Drug Interactions in Hepatic Endoplasmic Reticulum
Yukio Kato, Kanazawa University, Japan
Understanding CYP3A4 and P-gp Mediated Drug-Drug Interactions through PBPK Modeling - Case Example of Pralsetinib
Christine Bowman, Genentech, USACYP2C8 Clinical Probe Substrates and the Significance of OATP1B CYP Interplay: From Repaglinide to Daprodustat
Manthena Varma, Pfizer, USAAltered Transporter Function in Patients with Autosomal Dominant Polycystic Kidney Disease: Impact on Bile Acids, Coproporphyrin-I, Drug-Drug Interactions, and Drug-Induced Liver Injury
Jacqueline Tiley, UNC, USA
Symposium 2: Oral Delivery of bRo5 Compounds (Peptides, TPD)
Co-chairs: Simone Schadt, Roche, Switzerland; Donglu Zhang, Genentech, USA
Inroads with Gastrointestinal Permeation Enhancers for Oral Peptides
Mridula Dogra, Lilly, USAOral macromolecules: Bringing the unruly to heel
Stephen Buckley, Nova Nordisk, DenmarkNovel Approaches to deliver PROTACs to the site of action
Donglu Zhang, Genentech/Roche, USANovel strategies to assess and improve oral bioavailability of bRo5 compounds, including degraders and chameleonicity
Ryoichi Saito, Chugai Pharmaceutical Co., Ltd., Japan
12:00 - 15:00
Lunch/Exhibits/Poster Viewing/Thought Leader Presentations
Finalist Presentations
A1-A6 Finalist Presentations: 12:00 - 12:45
A7-A12 Finalist Presentations: 12:45 - 13:30
Poster Session 1 Presentations, P1-P45
Odd Poster Presentations: 13:30 - 14:15
Even Poster Presentations: 14:15 - 15:00
Thought Leader Presentation Schedule:
Pharmaron: 13:45 - 13:55
ATCC: 14:00 - 14:10
BioIVT: 14:15 - 14:25
15:00 - 16:30
Concurrent Symposia 3 & 4
Symposium 3: Nuclear Receptors in Drug Discovery and Development
Co-chairs: Huichang (Nancy) Bi, Southern Medical University, China; Taosheng Chen, St. Jude's Children's Research Hospital, USA
Multiple approaches to inhibit the xenobiotic receptor PXR
Taosheng Chen, St. Jude Children's Research Hospital, USANovel PXR/CAR modulators in long-term human primary hepatocyte culture
Hongbing Wang, Maryland University, USAStructure-informed discovery of a novel nuclear receptor ligand regulatory mechanism
Doug Kojetin, Scripps Research, USA
Symposium 4: Protein-based and novel modalities
Co-chairs: David Belair, Abbvie, USA; Nita Patel, Eli Lilly, USA
Overcoming ADME challenges of Antibody Conjugates (Diversified applications ADC/ARC)
Lukasz Chlewicki, Lilly, USAMechanistic PKPD Modeling for Therapeutic Protein Degraders/ADCs
David Belair, Abbvie, USAConsidering sub-cellular processes to enhance PKPD modeling and translation of Antibody Oligonucleotide Conjugates (AOCs)
Jessica Leete, Avidity BioSciences, USA
16:30 - 16:45
Break
16:45 - 18:15
ISSX Debate Session
Motion: This house believes that in silico models, in vitro studies, and artificial intelligence will replace in vivo studies as the primary decision-making tools in the preclinical sciences within the next decade.
Moderator: Andreas Reichel, Bayer, Germany
Robin Haid, Bayer, USA
Kevin Read, University of Dundee, UK
Ben-Filippo Krippendorff, Pierre Fabre Group, France
Steve Hood, GSK, UK